OmniAb, Inc.
OABI
NASDAQ·Healthcare·Biotechnology·Mkt cap $627.7M
$4.33
▼ -8.84%
P/E
-12.03
Mkt Cap
$627.7M
52-Wk Range
$1.30–$5.43
52-Week Range
$1.30 - $5.43
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 172.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary transgenic animal platform generating fully human antibodies, reducing development timelines and immunogenicity risks
- Diverse antibody repertoire access through multiple species-specific technologies addressing varied therapeutic applications
- Capital-efficient partnership model generating recurring licensing fees and royalties without heavy R&D burden
- Specialized platforms for bispecific and complex target antibodies addressing unmet industry needs
- Established relationships with major pharmaceutical and biotech companies providing revenue stability
Bear Case
1 risk
- Average volatility.
Growth
Mild headwinds expected
Premium gross margins (73%)
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+89.9% over 3m
Quality
Strong
High-growth business (67% revenue growth, 51% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying OABI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 6, 2026
Reported EPS of -$0.05 vs -$0.12 consensus (+58.3% surprise). Revenue of $13.4M vs $4.7M expected (+185.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+58.3%
Revenue trend · last 8Q
—
+124%
+9%
-49%
-46%
-22%
+247%
+244%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$4.2M
$10.8M
$4.2M
$3.9M
$2.2M
$8.4M
$14.4M
$13.4M
Margins · last 8Q
Gross
95.5%
Operating
-49.5%
Profit
-43.7%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How OABI stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related